Sponsors seeking clinical trial success must understand and manage collaboration among Key Opinion Leaders (KOLs), Principal Investigators (PIs), Medical Monitors (MMs), and Clinical Research Associates (CRAs). Conflicts between these roles can negatively affect trial timelines, data quality, and patient outcomes, so recognizing these dynamics early and implementing trust-building strategies is critical.

Here we identify common points of conflict and outline how sponsors can foster productive, trust-based engagement to ensure trial success.

The key to successful clinical trials

Running a clinical trial is complex, and many sponsors partner with a CRO to manage operational, logistical, and regulatory challenges. But not all CROs are created equal. Selecting a CRO with a reputation for responsiveness, clear communication, and collaboration enables sponsors to focus on research and development, accelerating time-to-market for new treatments.

In partnership with the sponsor, a CRO navigates interactions with sites, Key Opinion Leaders (KOLs), and Principal Investigators (PIs). A true CRO partner will take active ownership of the program, listen and adapt to evolving needs, and provide consistent access to knowledgeable experts. During a trial, Medical Monitors (MMs) and Clinical Research Associates (CRAs) are the CRO staff with whom sites, PIs, and KOLs interact most often. The relationships between all members of the clinical trial team can make or break the study – so understanding their roles and how to proactively manage the players is vital.

The players

KOLs provide strategic clinical insight. Their early scientific and clinical direction shapes protocol feasibility, endpoints, and positioning through advisory input. Their value is highest upstream, and at inflection (or reflection) points, rather than in day-to-day trial execution.

PIs provide site accountability. They own trial delivery at the site level, with direct responsibility for enrollment, patient management, data integrity, and compliance with regulatory and ethics requirements.

MMs provide clinical oversight and risk management. These licensed physicians safeguard patient safety, and protocol integrity, across the study. They translate complex safety signals into actionable guidance for sponsors and PIs, particularly during emerging or unexpected events.

CRAs provide operational control. They drive executional consistency across sites through initiation, monitoring, issue resolution, and data oversight. CRAs ensure timelines, quality standards, and vendor activities remain aligned with sponsor objectives.

MMs and CRAs serve as vital links in the communication chain among sponsors, KOLs, PIs, and other site personnel. While all parties are committed to conducting high-quality, ethical, and compliant research, tensions can often arise from diverging priorities or unclear communication. A committed CRO with thoughtful, transparent, and timely communication empowers MMs and CRAs to bridge divides and drive efficient, on-budget trial delivery.

Three ways to build those collaborative relationships

Turnover impacts trust the most. Extreme turnover, especially among CRAs, peaked between 2018 and 2021 [1]. In 2023, CRA turnover was reported at approximately 23% in the US [1], the highest among the various job roles in the clinical trial research program. CRAs also have a relatively short average tenure in their jobs – 3.3 years in 2023 (however, this is up from the previous two years) [1].

Consistency is key: ongoing relationships foster trust and accountability among KOLs and PIs, while high turnover disrupts these ties and can slow issue resolution. While some turnover is inevitable, sponsors can address this challenge by prioritizing CRO partners with reliable, professional teams and strong retention strategies, ensuring continuity of knowledge and expertise.

Supporting CRAs with manageable workloads and professional growth opportunities leads to longer tenures and more engaged site relationships. Forward-thinking sponsors also benefit from building long-term relationships with project managers and primary contacts, creating institutional memory and responsiveness that accelerate problem-solving.

Reshaping the role of the CRA is key. They are site champions and relationship managers, and not simply purely transactional data monitors; their focus on site relationships makes all the difference.

There are several reasons why additional oversight is needed in clinical trials. Strict regulatory oversight is increasingly prevalent with new and experimental treatments. Additionally, the need for greater data transparency, the use of electronic data capture (EDC), remote monitoring tools, and heightened awareness of patient ethics and safety mean that many more processes need to be discussed, developed, and documented.

For sponsors, the regulatory and operational environment demands increased oversight. However, every additional request or intervention – often delivered by MMs – can be perceived as a lack of trust in KOLs’ and PIs’ expertise. A thoughtful, transparent communication strategy can help reduce friction and reinforce the shared goals of patient safety and data integrity.

MMs must also reconcile the sponsor’s need for rapid, precise data generation with the needs of patient care and scientific credibility, while navigating the diverse requirements of various stakeholders. When this goes wrong, it can be catastrophic.

Effective oversight is a hallmark of clinical trial management, ensuring trials generate high-quality data [2]. MMs should be empowered to act as partners, actively engaging in joint review meetings, site advisory boards, and problem-solving sessions, to ensure effective collaboration. MMs can collaborate with CRAs to understand site-specific resources, expertise, and challenges for each trial, to tailor and support communication with site PIs and KOLs. CROs that offer transparent, proactive oversight not only yield better patient outcomes but also enhance the team’s reliability and flexibility.

profile picture for anupama acheson

Medical monitors bring real clinical experience, so they understand the realities and pressures faced by PIs in busy practices, and value the expertise KOLs contribute. These perspectives fuel genuine collaboration with the study team – a partnership that is deeply rewarding and invaluable to CRO teams and to sponsors working together to deliver meaningful options for patients.

Anupama Acheson, Director of Medical Monitoring and Consulting, PSI

Remote and risk-based monitoring (RBM) has resulted in improved trial efficiency [3] and reduced human error. This involves a combination of remote, centralized, and on-site monitoring, initiated through a risk analysis process to direct resources effectively to the most suitable locations. Routine data can generally be monitored remotely; however, risk assessments (or central findings) can initiate site visits or data reviews.

RBM has helped address ongoing resource constraints, reducing trial costs for sponsors. Meanwhile, technology has revolutionized clinical trials, with EDCs, centralized monitoring dashboards, and decentralized trial models increasing transparency, access, and the efficiency of performance metrics for sponsors.

However, the “human element” is at risk of being lost. As trials become increasingly digital, informal relationship-building and trust reinforcement require intentional effort. Without it, misunderstandings and disengagement become more likely. Championing initiatives that foster personal connection, such as regular virtual check-ins, collaborative problem-solving sessions, and recognition of site achievements, can help maintain a partnership mindset even in a remote environment.

With increased technology also comes increased data complexity and oversight. Some KOLs and PIs may view new tools as intrusive or overly burdensome. By involving CROs with technology specialists in early adoption discussions, and providing tailored training, sponsors can build buy-in and reduce resistance, ensuring that technology supports, not hinders, trusted relationships.

Site Support Specialists play a pivotal role in supporting busy sites by ensuring that the timely, accurate and consistent processing of study data is not burdensome to the site. They help streamline workflows, troubleshoot technology related issues and provide expert guidance, all of which enables investigators and their staff to focus on patient care and study progression without added complexities.

Key takeaways

Sponsors who prioritize and proactively seek out like-minded partners build resilient, high-performing teams: ones that minimize turnover, ensure milestones are met, and support on-time, on-budget trial delivery.

Leadership from sponsors sets the tone for a culture of transparency, partnership, and shared success. Every interaction is an opportunity to reinforce a shared vision: advancing patient care through efficient, credible, and ethical clinical research.

At PSI, we believe that genuine partnership and open communication between KOLs, PIs, site staff, and study teams are at the heart of every successful clinical trial.

If you share these priorities and would like to learn more, contact us today

Learn more

Abbreviations

CRA, Clinical Research Associate;
CRO, Contract Research Organization;
EDC, electronic data capture;
KOL, Key Opinion Leader;
MM, Medical Monitor;
PI, Principal Investigator;
RBM, remote and risk-based monitoring.

References

1. Canavan, J.B. and Radle-Moors, K., Key Findings from BDO’s 2024 Clinical Research Organization Global Compensation & Turnover Survey, in BDO USA. 2025.
2. McLaren, M., How quality clinical monitoring oversight ensures the success of clinical trials, in ClinicalTrials Arena. 2023.
3. Yamada, O., et al., Effectiveness of remote risk-based monitoring and potential benefits for combination with direct data capture. Trials, 2024. 25(1): p. 384.